Cara Therapeutics: Scratching At Multiple Indications In 2020 (NASDAQ:CARA) | Seeking Alpha
Difelikefalin - Wikipedia
A New Path to Pain Relief: Time for a Change with a Peripherally Acting Kappa Opioid Receptor Agonist (KORA)Friday, March 17, 201712:30 PM – 1:30 PMGrand Caribbean Ballroom 7Loews Sapphire Falls ResortOrlando, Florida Survey
A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus | NEJM
Articles with Cara Therapeutics, Inc. | page 5
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
Peripheral kappa opioid receptor activation drives cold hypersensitivity in mice | bioRxiv
PDF) Purification of a kappa-opioid receptor subtype from frog brain | Mária Szücs, Anna Borsodi, and Kálmán Medzihradszky - Academia.edu
EX-99.2
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Nephrology Journal Club on Twitter: "Difelikefalin (CR845) (KORSUVA) is a peripherally restricted, selective kappa opioid receptor agonist that exerts antipruritic effects by means of activation of kappa opioid receptors on peripheral neurons
Cara Therapeutics: Developing Novel Peripheral Kappa Opioid Product Candidates
CR845 (Difelikefalin), A Kappa Receptors Agonist In Phase III By CARA Therapeutics: A Case Of 'Spin' In Scientific Writing? | Semantic Scholar
PDF) Evaluation of the abuse potential of difelikefalin, a selective kappa‐ opioid receptor agonist, in recreational polydrug users
Kappa Opioid Receptor Ligands and Pharmacology: Diphenethylamines, a Class of Structurally Distinct, Selective Kappa Opioid Ligands | SpringerLink
Experimental Kappa Opioid Appears Safe and Effective
A systematic review on the kappa opioid receptor and its ligands: New directions for the treatment of pain, anxiety, depression, and drug abuse - ScienceDirect
Cara Therapeutics: Scratching An Itch Left Unscratched (NASDAQ:CARA) | Seeking Alpha
New Kappa-Opioid Receptor Agonist Curbs Pain, Avoids Side Effects
Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects | Journal of Pharmacology and Experimental Therapeutics
Cara Therapeutics: Scratching An Itch Left Unscratched (NASDAQ:CARA) | Seeking Alpha
Frontiers | Advances in Achieving Opioid Analgesia Without Side Effects
Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Mark
1Washington University, St. Louis, MO, USA; 2Trevi Therapeutics, New Haven, CT, USA; 3University of Miami, Miami, FL, USA Introd
Kappa-opioid receptor-dependent changes in dopamine and anxiety-like or approach-avoidance behavior occur differentially across the nucleus accumbens shell rostro-caudal axis,Neuropharmacology - X-MOL
Cara Therapeutics - Invest In Weed
Peptide Kappa Opioid Receptor Ligands and Their Potential for Drug Development | SpringerLink
